Hanall Biopharma Drives Innovation: New Drugs for Autoimmune, Cancer, & Hypertension Ahead of 2026
Discover Hanall Biopharma’s breakthrough pipeline—from anti‑FcRn HL161 for autoimmune disorders to HL036 for dry eye—and its ambitious growth in the Korean pharma market.
2 minutes to read